Thrombus　is　one　of　the　culprits　for　global　health　problems.　However,　most　current　antithrombotic　drugs　are　limited　by　restricted　targeting　ability　and　a　high　risk　of　systemic　bleeding.　A　hybrid　cell　membrane-coated　biomimetic　nanosystem　(PM/RM@PLGA@P/R)　was　constructed　in　this　paper　to　fulfil　the　targeted　delivery　of　ginsenoside　(Rg1)　and　perfluorohexane　(PFH).　Poly　lactic-co-glycolic　acid　(PLGA)　is　used　as　carriers　to　coat　Rg1　and　PFH.　Thanks　to　the　camouflage　of　erythrocyte　membrane　(RM)　and　platelet　membrane　(PM),　the　nanosystem　in　question　possesses　remarkable　features　including　immune　escape　and　self-targeting.　Therefore,　a　compact　nano-core　with　PLGA@P/R　was　formed,　with　a　hybrid　membrane　covering　the　surface　of　the　core,　forming　a　＂core-shell＂　structure.　With　its　＂core-shell＂　structure,　this　nanoparticle　fancifully　combines　the　advantages　of　both　PFH　(the　low-intensity　focused　ultrasound　(LIFU)-responsive　phase-change　thrombolysis)　and　Rg1(the　antioxidant,　anti-inflammatory　and　anticoagulant　abilities).　Meanwhile,　PM/RM@PLGA@P/R　nanoparticles　exhibits　superior　in-vitro　performance　in　terms　of　ROS　scavenging,　anticoagulant　activity　and　immune　escape　compared　with　those　without　cell　membranes　(PLGA@P/R).　Furthermore,　in　the　animal　experiment　in　which　the　tail　vein　thrombosis　model　was　established　by　injecting　k-carrageenan,　the　combined　treatment　of　LIFU　and　PM/　RM@PLGA@P/R　showed　a　satisfactory　antithrombotic　efficiency　(88.20　%)　and　a　relatively　higher　biological　safety　level.　This　strategy　provides　new　insights　into　the　development　of　more　effective　and　safer　targeted　biomimetic　nanomedicines　for　antithrombotic　treatments,　possessing　potential　application　in　synergistic　therapy　field.